Editorial
On January 1, 2011, I appointed 65 eminent scientists for 3-year terms on the Journal of Pharmaceutical Sciences (JPharmSci ) Editorial Advisory Board (EAB). The term of these individuals will expire on December 31, 2013. I am pleased to announce here that the following individuals have accepted reappointments to the JPharmSci EAB for another 3-year term (January 1, 2014–December 31, 2016): Gregory E. Amidon, University of Michigan; Thomas J. Anchordoquy, University of Colorado Denver; Per Artursson, Uppsala University; Patrick Augustijns, KU Leuven; Bruce J. Aungst, QPS, LLC; Joseph P. Balthasar, University at Buffalo; Sathy V. Balu-Iyer, SUNY—University at Buffalo; Robin H. Bogner, University of Connecticut; Ben J. Boyd, Monash University; Kenneth R. Brouwer, Qualyst Transporter Solutions; Stephen R. Byrn, Purdue University; Adeola O. Coker, University of the Incarnate Word; Duncan Q. M. Craig, UCL School of Pharmacy; Martyn Davies, University of Nottingham; Yoshiharu Deguchi, Teikyo University; Jennifer Dressman, J.W. Goethe University; Henrik Gr´een, Link¨oping University; Michael J. Hageman, Bristol-Myers Squibb; Margareta Hammarlund-Udenaes, Uppsala University; Ken-ichi Hosoya, University of Toyama; Ken-ichi Izutsu, National Institute of Health Sciences; Kevin C. Johnson, Intellipharm, LLC; David S. Jones, Queen’s University at Belfast; Vitaliy Khutoryanskiy, University of Reading; Peter Kleinebudde, Heinrich-Heine-University Duesseldorf; Janet G. Koe, JGIJ Consulting, LLC; Robert ¨ Langer, MIT; Jean-Christophe Leroux, ETH Zurich; Thorsteinn Loftsson, University of Iceland; Michael B. Maurin, Maurin Healthcare Consulting; S. Narasimha Murthy, The University of Mississippi; Steven L. Nail, Baxter Medical Products R&D; Linda O. Narhi, Amgen, Inc.; Sumio Ohtsuki, Kumamoto University; Mike Pikal, University of Connecticut; Richard J. Prankerd, Monash University; Theodore Randolph, University of Colorado, Boulder; Susan M. Reutzel-Edens, Eli Lilly & Company; Kevin G. Rice, University of Iowa; Nair RodriguezHornedo, The University of Michigan; Mark C. Rogge, Biogen Idec, Inc.; Amy S. Rosenberg, Center for Drug Evaluation and Research/United States Food and Drug Administration (FDA); Chandrahas Sahajwalla, FDA; Abu T. M. Serajuddin, St. John’s University; Danny D. Shen, University of Washington; Teruna J. Siahaan, The University of Kansas; Valentino J. Stella, The University of Kansas; Audra Stinchcomb, University of Kentucky and AllTranz Inc.; Yun K. Tam, Sinoveda Canada Inc.; Dhiren R. Thakker, University of North Carolina at Chapel Hill; Geert Verreck, Janssen Research & Development; David Volkin, The University of Kansas; Adrian C. Williams, University of Reading; Gerhard Winter, University of Munich (LMU); Akira Yamamoto, Kyoto Pharmaceutical University; Hiroshi Yamazaki, Showa Pharmaceutical University; and Gaylen M. Zentner, Comprehensive CMC Outsourcing, LLC. R
R
Journal of Pharmaceutical Sciences, Vol. 103, 352 (2014) C 2013 Wiley Periodicals, Inc. and the American Pharmacists Association
352
Borchardt, JOURNAL OF PHARMACEUTICAL SCIENCES 103:352, 2014
I would like to publicly thank the following individuals who have served on the JPharmSci EAB for the past 3 years and who will retire from the EAB effective December 31, 2013: J. A. Bouwstra, LACDR, Leiden University; Elizabeth C. M. de Lange, Leiden/Amsterdam Center for Drug Research; M. Jayne Lawrence, King’s College London; James W. McGinity, University of Texas; Sudax Murdan, University of London; Steven P. Schwendeman, The University of Michigan; Ping Yeh, Biogen Idec, Inc.; and Lian Yu, University of Wisconsin-Madison. I am also pleased to announce here the appointment of 17 new EAB members for a 3-year term starting on January 1, 2014. These new members of the JPharmSci EAB include: James G. Bann, Wichita State University; Michael Blaber, Florida State University; James Butler, GlaxoSmithKline; Mark T. Fisher, University of Kansas Medical Center; Kosalaram Goteti, MedImmune; Mark McAllister, Pfizer; Ashwini Nangia, University of Hyderabad; Marino Nebuloni, REDOX and Parma University; Thanh Nguyen, University College London; Hanne Mørck Nielsen, University of Copenhagen; Takuo Ogihara, Takasaki University of Health and Welfare; Krishnan Sampath, Hospira Inc.; Robert G. Strickley, Gilead Sciences, Inc.; Susumu Uchiyama, Osaka University; Guangji Wang, China Pharmaceutical University; J. Axel Zeitler, University of Cambridge; and Lucia Zema, Universita` degli Studi di Milano. With these reappointments and new appointments to the JPharmSci EAB, this advisory group in 2014 will consist of 174 members. JPharmSci ’s Editors and I feel that the composition of the EAB appropriately reflects the diversity of scientific disciplines served by the journal and the diversity of its international audience. In addition, I feel that the EAB is sufficiently large to ensure that an adequate number of experts are available to conduct timely reviews of the approximately 1050 manuscripts per year that are submitted to JPharmSci . Finally, I would like to take this opportunity to thank the EAB members and the Editors for their dedication to JPharmSci and for the time and energy they have spent in the past 12.5 years helping me as an Editor-in-Chief to further strengthen this journal and to better serve pharmaceutical scientists worldwide. R
R
R
R
R
R
Ronald T. Borchardt Editor-in-Chief Journal of Pharmaceutical Sciences Received 12 December 2013; accepted 13 December 2013 Published online 30 December 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.23842
On January 1, 2011, I appointed 65 eminent scientists for 3-year terms on the Journal of Pharmaceutical Sciences (JPharmSci ) Editorial Advisory Board (EAB). The term of these individuals will expire on December 31, 2013. I am pleased to announce here that the following individuals have accepted reappointments to the JPharmSci EAB for another 3-year term (January 1, 2014–December 31, 2016): Gregory E. Amidon, University of Michigan; Thomas J. Anchordoquy, University of Colorado Denver; Per Artursson, Uppsala University; Patrick Augustijns, KU Leuven; Bruce J. Aungst, QPS, LLC; Joseph P. Balthasar, University at Buffalo; Sathy V. Balu-Iyer, SUNY—University at Buffalo; Robin H. Bogner, University of Connecticut; Ben J. Boyd, Monash University; Kenneth R. Brouwer, Qualyst Transporter Solutions; Stephen R. Byrn, Purdue University; Adeola O. Coker, University of the Incarnate Word; Duncan Q. M. Craig, UCL School of Pharmacy; Martyn Davies, University of Nottingham; Yoshiharu Deguchi, Teikyo University; Jennifer Dressman, J.W. Goethe University; Henrik Gr´een, Link¨oping University; Michael J. Hageman, Bristol-Myers Squibb; Margareta Hammarlund-Udenaes, Uppsala University; Ken-ichi Hosoya, University of Toyama; Ken-ichi Izutsu, National Institute of Health Sciences; Kevin C. Johnson, Intellipharm, LLC; David S. Jones, Queen’s University at Belfast; Vitaliy Khutoryanskiy, University of Reading; Peter Kleinebudde, Heinrich-Heine-University Duesseldorf; Janet G. Koe, JGIJ Consulting, LLC; Robert ¨ Langer, MIT; Jean-Christophe Leroux, ETH Zurich; Thorsteinn Loftsson, University of Iceland; Michael B. Maurin, Maurin Healthcare Consulting; S. Narasimha Murthy, The University of Mississippi; Steven L. Nail, Baxter Medical Products R&D; Linda O. Narhi, Amgen, Inc.; Sumio Ohtsuki, Kumamoto University; Mike Pikal, University of Connecticut; Richard J. Prankerd, Monash University; Theodore Randolph, University of Colorado, Boulder; Susan M. Reutzel-Edens, Eli Lilly & Company; Kevin G. Rice, University of Iowa; Nair RodriguezHornedo, The University of Michigan; Mark C. Rogge, Biogen Idec, Inc.; Amy S. Rosenberg, Center for Drug Evaluation and Research/United States Food and Drug Administration (FDA); Chandrahas Sahajwalla, FDA; Abu T. M. Serajuddin, St. John’s University; Danny D. Shen, University of Washington; Teruna J. Siahaan, The University of Kansas; Valentino J. Stella, The University of Kansas; Audra Stinchcomb, University of Kentucky and AllTranz Inc.; Yun K. Tam, Sinoveda Canada Inc.; Dhiren R. Thakker, University of North Carolina at Chapel Hill; Geert Verreck, Janssen Research & Development; David Volkin, The University of Kansas; Adrian C. Williams, University of Reading; Gerhard Winter, University of Munich (LMU); Akira Yamamoto, Kyoto Pharmaceutical University; Hiroshi Yamazaki, Showa Pharmaceutical University; and Gaylen M. Zentner, Comprehensive CMC Outsourcing, LLC. R
R
Journal of Pharmaceutical Sciences, Vol. 103, 352 (2014) C 2013 Wiley Periodicals, Inc. and the American Pharmacists Association
352
Borchardt, JOURNAL OF PHARMACEUTICAL SCIENCES 103:352, 2014
I would like to publicly thank the following individuals who have served on the JPharmSci EAB for the past 3 years and who will retire from the EAB effective December 31, 2013: J. A. Bouwstra, LACDR, Leiden University; Elizabeth C. M. de Lange, Leiden/Amsterdam Center for Drug Research; M. Jayne Lawrence, King’s College London; James W. McGinity, University of Texas; Sudax Murdan, University of London; Steven P. Schwendeman, The University of Michigan; Ping Yeh, Biogen Idec, Inc.; and Lian Yu, University of Wisconsin-Madison. I am also pleased to announce here the appointment of 17 new EAB members for a 3-year term starting on January 1, 2014. These new members of the JPharmSci EAB include: James G. Bann, Wichita State University; Michael Blaber, Florida State University; James Butler, GlaxoSmithKline; Mark T. Fisher, University of Kansas Medical Center; Kosalaram Goteti, MedImmune; Mark McAllister, Pfizer; Ashwini Nangia, University of Hyderabad; Marino Nebuloni, REDOX and Parma University; Thanh Nguyen, University College London; Hanne Mørck Nielsen, University of Copenhagen; Takuo Ogihara, Takasaki University of Health and Welfare; Krishnan Sampath, Hospira Inc.; Robert G. Strickley, Gilead Sciences, Inc.; Susumu Uchiyama, Osaka University; Guangji Wang, China Pharmaceutical University; J. Axel Zeitler, University of Cambridge; and Lucia Zema, Universita` degli Studi di Milano. With these reappointments and new appointments to the JPharmSci EAB, this advisory group in 2014 will consist of 174 members. JPharmSci ’s Editors and I feel that the composition of the EAB appropriately reflects the diversity of scientific disciplines served by the journal and the diversity of its international audience. In addition, I feel that the EAB is sufficiently large to ensure that an adequate number of experts are available to conduct timely reviews of the approximately 1050 manuscripts per year that are submitted to JPharmSci . Finally, I would like to take this opportunity to thank the EAB members and the Editors for their dedication to JPharmSci and for the time and energy they have spent in the past 12.5 years helping me as an Editor-in-Chief to further strengthen this journal and to better serve pharmaceutical scientists worldwide. R
R
R
R
R
R
Ronald T. Borchardt Editor-in-Chief Journal of Pharmaceutical Sciences Received 12 December 2013; accepted 13 December 2013 Published online 30 December 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.23842
